Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

Br J Haematol. 2017 Mar;176(6):888-907. doi: 10.1111/bjh.14514. Epub 2017 Jan 20.


A growing population of long-term survivors of myeloma is now accumulating the 'late effects' not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease. It is thus important to recognise the cumulative burden of the disease and treatment-related toxicity in both the stable and active phases of myeloma, some of which is unlikely to be detected by routine monitoring. We summarise here the evidence for the key late effects in long-term survivors of myeloma, including physical and psychosocial consequences (in Parts 1 and 2 respectively), and recommend the use of late-effects screening protocols in detection and intervention. The early recognition of late effects and effective management strategies should lead to an improvement in the management of myeloma patients, although evidence in this area is currently limited and further research is warranted.

Keywords: chemotherapy; haematopoietic stem cell transplantation; late effects; myeloma; quality of life.

Publication types

  • Practice Guideline

MeSH terms

  • Disease Management
  • Humans
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / psychology
  • Multiple Myeloma / rehabilitation
  • Multiple Myeloma / therapy*
  • Outcome Assessment, Health Care
  • Quality of Life
  • Survivors / psychology
  • Time Factors